Genetic analysis of TP53 in childhood myelodysplastic syndrome and juvenile myelomonocytic leukemia

Leukemia Research

Volumn 35, Issue 12, 2011, Pages 1578-1584

  Saito, Shoji ^a   Matsuda, Kazuyuki ^b   Taira, Chiaki ^b   Sano, Kenji ^b   Tanaka Yanagisawa, Miyuki ^a   Yanagisawa, Ryu ^a   Nakazawa, Yozo ^a   Sakashita, Kazuo ^a   Shiohara, Masaaki ^a   Koike, Kenichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Biallelic inactivation; Childhood; Clone; JMML; MDS; MLL duplication; TP53

Indexed keywords

CELL PROTEIN; CYCLOPHOSPHAMIDE; DNA; FLUDARABINE; K RAS PROTEIN; METHYLPREDNISOLONE; N RAS PROTEIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; TACROLIMUS; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CANCER RESISTANCE; CHILD; CHROMOSOME DELETION; CHROMOSOME DELETION 17; CHROMOSOME DELETION 5; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DONOR LYMPHOCYTE INFUSION; ERYTHROID CELL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE DUPLICATION; GENE INACTIVATION; GENE MUTATION; GENETIC ANALYSIS; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INFANT; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKOCYTE; MALE; MENTAL DEFICIENCY; MOLECULAR CLONING; MYELODYSPLASTIC SYNDROME; NEWBORN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; SCHOOL CHILD; SHORT STATURE; SPECTRAL KARYOTYPING; TP53 GENE; TUMOR SUPPRESSOR GENE; WHOLE BODY RADIATION;

ADOLESCENT; AGE OF ONSET; BASE SEQUENCE; CELLS, CULTURED; CHEMORADIOTHERAPY; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 5; CYTOGENETIC ANALYSIS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE DELETION; GENES, P53; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MALE; MYELODYSPLASTIC SYNDROMES; MYELOID-LYMPHOID LEUKEMIA PROTEIN; RADIATION TOLERANCE;

EID: 80055102659     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.06.027     Document Type: Article

References (28)

1. Fenaux P., Jonveaux P., Quiquandon I., Laï J.L., Pignon J.M., Loucheux-Lefebvre M.H., et al. P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 1991, 78:1652-1657.
2. Lai J.L., Preudhomme C., Zandecki M., Flactif M., Vanrumbeke M., Lepelley P. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations. Leukemia 1995, 9:370-381.
3. Haferlach C., Dicker F., Herholz H., Schnittger S., Kern W., Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008, 22:1539-1541.
4. Kita-Sasai Y., Horiike S., Misawa S., Kaneko H., Kobayashi M., Nakao M., et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br J Haematol 2001, 115:309-312.
5. Seifert H., Mohr B., Thiede C., Oelschlägel U., Schäkel U., Illmer T., et al. Study Alliance Leukemia (SAL). The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia 2009, 23:656-663.
6. Felix C.A., Hosler M.R., Provisor D., Salhany K., Sexsmith E.A., Slater D.J., et al. The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood 1996, 87:4376-4381.
7. Silveira C.G., Oliveira F.M., Valera E.T., Ikoma M.R., Borgonovo T., Cavalli I.J., et al. New recurrent deletions in the PPARgamma and TP53 genes are associated with childhood myelodysplastic syndrome. Leukemia Res 2009, 33:19-27.
8. Koike K., Matsuda K. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. Br J Haematol 2008, 141:567-575.
9. Loh M.L., Sakai D.S., Flotho C., Kang M., Fliegauf M., Archambeault S., et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009, 114:1859-1863.
10. Sugimoto Y., Muramatsu H., Makishima H., Prince C., Jankowska A.M., Yoshida N., et al. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. Br J Haematol 2010, 150:83-87.
11. Swerdlow S., Campo E., Lee Harris N., Jaffe E., Pileri S., Stein H., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC Press. 4th ed.
12. Matsuda K., Matsuzaki S., Miki J., Hidaka E., Yanagisawa R., Nakazawa Y., et al. Chromosomal change during 6-mercaptopurine (6-MP) therapy in juvenile myelomonocytic leukemia: the growth of a 6-MP-refractory clone that already exists at onset. Leukemia 2006, 20:485-490.
13. Mitani K., Hangaishi A., Imamura N., Miyagawa K., Ogawa S., Kanda Y., et al. No concomitant occurence of the N-ras and p53 gene mutations in myelodyplastic syndromes. Leukemia 1997, 11:863-865.
14. Tartaglia M., Martinelli S., Cazzaniga G., Cordeddu V., Iavarone I., Spinelli M., et al. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 2004, 104:307-313.
15. Kosaki K., Suzuki T., Muroya K., Hasegawa T., Sato S., Matsuo N., et al. PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome. J Clin Endocrinol Metab 2002, 87:3529-3533.
16. Kiyoi H., Naoe T., Nakano Y., Yokota S., Minami S., Miyawaki S., et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999, 93:3074-3080.
17. Spritz R.A., Giebel L.B., Holmes S.A. Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism. Am J Hum Genet 1992, 50:261-269.
18. Jekic B., Novakovic I., Lukovic L., Kuzmanovic M., Popovic B., Milasin J., et al. Lack of TP53 and FMS gene mutations in children with myelodysplastic syndrome. Cancer Genet Cytogenet 2006, 166:163-165.
19. Narumi Y., Aoki Y., Niihori T., Neri G., Cavé H., Verloes A., et al. Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome. Am J Med Genet A 2007, 143A:799-807.
20. Kosmider O., Gelsi-Boyer V., Slama L., Dreyfus F., Beyne-Rauzy O., Quesnel B., et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010, 24:1094-1096.
21. Kobayashi N., Matsuda K., Sakashita K., Matsuzaki S., Iwasaki R., Koike K. Bilineage acute leukemia of T-lymphoid and myeloid lineages. Haematologica 2004, 89:1139-1141.
22. Hidaka E., Tanaka M., Matsuda K., Ishikawa-Matsumura M., Yamauchi K., Sano K., et al. A complex karyotype, including a three-way translocation generating a NUP98-HOXD13 transcript, in an infant with acute myeloid leukemia. Cancer Genet Cytogenet 2007, 176:137-143.
23. Andersen M.K., Christiansen D.H., Kirchhoff M., Pedersen-Bjergaard J. Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents. Genes Chromosomes Cancer 2001, 31:33-41.
24. Tauscher M., Göhring G., Glaser S., Hofmann W., Feurstein S., Flotho C., et al. Clonal heterogeneity in childhood myelodysplastic syndromes-challenge for the detection of chromosomal imbalances by array-CGH. Genes Chromosomes Cancer 2010, 49:885-900.
25. De Filippi P., Zecca M., Lisini D., Rosti V., Cagioni C., Carlo-Stella C., et al. Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia. Br J Haematol 2009, 147:706-709.
26. Niemeyer C.M., Kang M.W., Shin D.H., Furlan I., Erlacher M., Bunin N.J., et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 2010, 42:794-800.
27. Christiansen D.H., Andersen M.K., Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001, 19:1405-1413.
28. Castro P.D., Liang J.C., Nagarajan L. Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms. Blood 2000, 95:2138-2143.